MarketCapExport financials
Nephros (NEPH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Nephros Balance Sheet 2025-2009 | NEPH
Brief overview of Nephros's balance sheet structure
This overview follows the five latest available annual observations between 2021 and 2025.
Assets fell from $17.6 million to $13.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities grew faster than assets: +18.5% versus -22.7%. A substantial part of expansion was externally funded.
Equity accounts for 74.8% of assets. Against the initial 66.3%, the capital position looks resilient.
Net debt moved below zero to -$5 million, reflecting surplus cash over debt.
Cash accounts for 39.6% of assets versus 39.5% initially. The change indicates the degree of financial flexibility.
The accumulated result is -$143.1 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
Nephros's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Nephros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5 M | -3.4 M | -2.48 M | -3.25 M | -6.65 M | -7.17 M | -2.77 M | -2.55 M | -529 K | 590 K | -1.25 M | -1.28 M | 779 K | -47 K | -1.67 M | - | - |
Long Term Debt |
11 K | 17 K | 1.39 M | 71 K | 12 K | 853 K | 623 K | 843 K | 954 K | 838 K | - | - | - | - | - | - | - |
Long Term Debt Current |
386 K | 343 K | 442 K | 309 K | 313 K | 332 K | 262 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 1.61 M | 1.51 M | 1.11 M | 1.16 M | 1.12 M | 347 K | 7.8 M | - | 707 K | - | - | - |
Total Current Liabilities |
2.77 M | 1.56 M | 2.11 M | 1.41 M | 2.39 M | 1.32 M | 2.43 M | 2.65 M | 1.87 M | 895 K | 959 K | 1.25 M | 3.5 M | 3.42 M | 2.57 M | 1.46 M | - |
Total Liabilities |
3.44 M | 2.62 M | 3.5 M | 2.12 M | 2.9 M | 2.94 M | 3.94 M | 3.76 M | 3.03 M | 2.01 M | 1.31 M | 9.05 M | 3.5 M | 4.12 M | 2.57 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 70 K | 70 K | 70 K | 70 K | 703 K | - | 2.09 M | 33 K | - |
Retained Earnings |
-143 M | -144 M | -144 M | -143 M | -136 M | -132 M | -127 M | -124 M | -121 M | -120 M | -117 M | -114 M | -101 M | -97.5 M | -94.3 M | -94.5 M | -98.4 M |
Total Assets |
13.6 M | 11.2 M | 11.9 M | 11 M | 17.6 M | 18.5 M | 11.6 M | 10.6 M | 4.98 M | 2.68 M | 3.97 M | 3.37 M | 2.89 M | 3.53 M | 3.99 M | 1.59 M | - |
Cash and Cash Equivalents |
5.4 M | 3.76 M | 4.31 M | 3.63 M | 6.97 M | 8.25 M | - | 4.58 M | 2.19 M | 275 K | 1.25 M | 1.28 M | 579 K | 47 K | 1.67 M | 240 K | 1 M |
Book Value |
10.2 M | 8.58 M | 8.36 M | 8.88 M | 14.7 M | 15.6 M | 7.69 M | 6.8 M | 1.95 M | 667 K | 2.66 M | -5.68 M | -610 K | -595 K | 1.42 M | 1.59 M | - |
Total Shareholders Equity |
10.2 M | 8.58 M | 8.36 M | 5.59 M | 11.7 M | 12.5 M | 4.68 M | 3.8 M | 1.95 M | 667 K | 2.66 M | -5.68 M | -610 K | -595 K | 1.42 M | 135 K | 1.96 M |
All numbers in USD currency
Quarterly Balance Sheet Nephros
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
661 K | 10 K | 1.05 M | 13 K | 14 K | 16 K | 17 K | 18 K | 1.22 M | 1.31 M | 1.39 M | 469 K | 534 K | 2 K | 4 K | 141 K | 210 K | 277 K | 12 K | 407 K | 470 K | 532 K | 593 K | 652 K | 711 K | 768 K | 824 K | 879 K | 933 K | 986 K | 1.04 M | 1.09 M | 1.14 M | - | 954 K | 954 K | 954 K | 954 K | 838 K | 838 K | 838 K | 838 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.44 M | 3.09 M | 2.62 M | 3.24 M | 2.64 M | 2.49 M | 2.62 M | 2.21 M | 3.17 M | 3.24 M | 3.5 M | 2.3 M | 1.73 M | 2.03 M | 2.12 M | 1.75 M | 2.47 M | 2.13 M | 2.9 M | 2.49 M | 3 M | 2.4 M | 2.94 M | 2.94 M | 2.94 M | 2.94 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 3.03 M | 3.03 M | 3.03 M | 3.03 M | 2.01 M | 2.01 M | 2.01 M | 2.01 M | 1.31 M | 1.31 M | 1.31 M | 1.31 M | 9.05 M | 9.05 M | 9.05 M | 9.05 M | 6.61 M | 3.5 M | 3.5 M | 3.5 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 2.57 M | 2.57 M | 2.57 M | 2.57 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 703 K | 703 K | 703 K | 703 K | 707 K | 707 K | 707 K | 707 K | 698 K | 698 K | 698 K | 698 K |
Retained Earnings |
-143 M | -143 M | -144 M | -143 M | -144 M | -144 M | -144 M | -145 M | -145 M | -145 M | -144 M | -144 M | -144 M | -143 M | -143 M | -142 M | -139 M | -138 M | -136 M | -135 M | -134 M | -132 M | -132 M | -132 M | -132 M | -132 M | -127 M | -127 M | -127 M | -127 M | -124 M | -124 M | -124 M | -124 M | -121 M | -121 M | -121 M | -121 M | -120 M | -120 M | -120 M | -120 M | -117 M | -117 M | -117 M | -117 M | -114 M | -114 M | -114 M | -114 M | -107 M | -101 M | -101 M | -101 M | -108 M | -97.5 M | -97.5 M | -97.5 M | -101 M | -94.3 M | -94.3 M | -94.3 M |
Total Assets |
13.6 M | 13.8 M | 11.2 M | 13.2 M | 12.2 M | 11.8 M | 11.2 M | 10.4 M | 11.1 M | 11.4 M | 11.9 M | 10.9 M | 10.4 M | 10.9 M | 11 M | 11.3 M | 15 M | 15.5 M | 17.6 M | 17.8 M | 18 M | 17.9 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 4.98 M | 4.98 M | 4.98 M | 4.98 M | 2.68 M | 2.68 M | 2.68 M | 2.68 M | 3.97 M | 3.97 M | 3.97 M | 3.97 M | 3.37 M | 3.37 M | 3.37 M | 3.37 M | 2.89 M | 2.89 M | 2.89 M | 2.89 M | 3.53 M | 3.53 M | 3.53 M | 3.53 M | 3.99 M | 3.99 M | 3.99 M | 3.99 M |
Cash and Cash Equivalents |
5.4 M | 4.02 M | 3.76 M | 5.17 M | 5.07 M | 4.08 M | 3.76 M | 2.46 M | 3.08 M | 3.63 M | 4.31 M | 4.62 M | 4.06 M | 3.84 M | 3.63 M | 3.94 M | 4.18 M | 5.42 M | 6.97 M | 7.35 M | 8.28 M | 8.16 M | 8.25 M | 8.25 M | 8.25 M | 8.25 M | 4.17 M | 4.17 M | 4.17 M | 4.17 M | 4.58 M | 4.58 M | 4.58 M | 4.58 M | 2.19 M | 2.19 M | 2.19 M | 2.19 M | 275 K | 275 K | 275 K | 275 K | 1.25 M | 1.25 M | 1.25 M | 1.25 M | 1.28 M | 1.28 M | 1.28 M | 1.28 M | 579 K | 579 K | 579 K | 579 K | 47 K | 47 K | 47 K | 47 K | 1.67 M | 1.67 M | 1.67 M | 1.67 M |
Book Value |
10.2 M | 10.7 M | 8.58 M | 10 M | 9.6 M | 9.29 M | 8.58 M | 8.17 M | 7.93 M | 8.18 M | 8.36 M | 8.62 M | 8.66 M | 8.89 M | 8.88 M | 9.58 M | 12.5 M | 13.4 M | 14.7 M | 15.3 M | 15 M | 15.5 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 7.69 M | 7.69 M | 7.69 M | 7.69 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 1.95 M | 1.95 M | 1.95 M | 1.95 M | 667 K | 667 K | 667 K | 667 K | 2.66 M | 2.66 M | 2.66 M | 2.66 M | -5.68 M | -5.68 M | -5.68 M | -5.68 M | -3.72 M | -610 K | -610 K | -610 K | -595 K | -595 K | -595 K | -595 K | 1.42 M | 1.42 M | 1.42 M | 1.42 M |
Total Shareholders Equity |
8.58 M | 10.7 M | 8.36 M | 10 M | 9.6 M | 9.29 M | 8.58 M | 8.17 M | 7.93 M | 8.18 M | 8.36 M | 8.62 M | 8.66 M | 8.89 M | 5.59 M | 9.58 M | 12.5 M | 13.4 M | 11.7 M | 15.3 M | 15 M | 15.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 4.68 M | 4.68 M | 4.68 M | 4.68 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 1.95 M | 1.95 M | 1.95 M | 1.95 M | 667 K | 667 K | 667 K | 667 K | -2.66 M | 2.66 M | 2.66 M | 2.66 M | -5.68 M | -5.68 M | -5.68 M | -5.68 M | -3.72 M | -610 K | -610 K | -610 K | -595 K | -595 K | -595 K | -595 K | 1.42 M | 1.42 M | 1.42 M | 1.42 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Nephros, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 106.82 | 0.01 % | $ 5.04 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 111.75 | 1.1 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.99 | 8.13 % | $ 293 M | USA |
 |
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | USA |
 |
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | USA |
 |
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | USA |
 |
BioLife Solutions
BLFS
|
$ 37.74 | 0.37 % | $ 1.8 B | USA |
 |
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |